SCHEMBL12207239

SCHEMBL12207239

O=C(O)[C@H](Cc1ccccc1)NCCN[C@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MME P08473 3/20 0.57
NPSR1 Q6W5P4 1/20 0.56
CYP1A2 P05177 1/20 0.55
NAALAD2 Q9Y3Q0 2/20 0.54
FOLH1 Q04609 1/20 0.53
MMP2 P08253 4/20 0.53
MMP9 P14780 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ADAMTS4 O75173 1/20 0.53
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC7A5 Q01650 1/20 0.52
ACE P12821 1/20 0.51
CPA1 P15085 1/20 0.51
ACE2 Q9BYF1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7596254 1.00 MME (0.57) MMENPSR1CYP1A2NAALAD2FOLH1
SCHEMBL995917 0.91 NPSR1 (0.55) MMENPSR1CYP1A2NAALAD2FOLH1
SCHEMBL27699635 0.91 MME (0.56) MMENPSR1NAALAD2ACECPA1
SCHEMBL27699637 0.91 MME (0.56) MMENPSR1NAALAD2ACECPA1
SCHEMBL30673629 0.89 MME (0.51) MMENPSR1CYP1A2NAALAD2FOLH1
SCHEMBL31688792 0.89 SIGMAR1 (0.59) MMENPSR1CYP1A2NAALAD2MMP2
SCHEMBL3343350 0.89 SIGMAR1 (0.59) MMENPSR1CYP1A2NAALAD2MMP2
SCHEMBL29091477 0.89 MME (0.51) MMENPSR1CYP1A2NAALAD2FOLH1
SCHEMBL547203 0.89 NAALAD2 (0.60) MMENPSR1CYP1A2NAALAD2ACE
SCHEMBL661567 0.89 SIGMAR1 (0.59) MMENPSR1CYP1A2NAALAD2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014291-B1 Piperazinone compounds as anti-tumor and anti-cancer agents UNIV YALE (US) 2011-10-26 EP disclosed
US-7763620-B2 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment YALE UNIVERSITY (US) 2010-07-27 US disclosed
EP-1427418-B1 PIPERAZINONE COMPOUNDS AS ANTI-TUMOR AND ANTI-CANCER AGENTS UNIV YALE (US) 2009-11-11 EP disclosed
EP-2014291-A2 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment YALE UNIVERSITY (US) 2009-01-14 EP disclosed
US-20080221123-A1 Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and Methods of Treatment YALE UNIVERSITY 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221123-A1 Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and Methods of Treatment EP300, HDAC5, VHL MME 3314/4885NPSR1 3836/4885CYP1A2 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.